Literature DB >> 24416637

Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal.

Kerri Johannson1, Harold R Collard2.   

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (IPF) occurs in roughly 10% of patients annually, and is a leading cause of morbidity and mortality in this disease. While currently defined as idiopathic acute worsenings, acute exacerbations of IPF may in fact have a variety of causes, in particular infection and aspiration. Central to the pathobiology of clinically meaningful events is a diffuse injury to the IPF lung manifest histopathologically as diffuse alveolar damage, and biologically as accelerated alveolar epithelial cell injury or repair. Based on these recent observations, we propose a new paradigm for acute exacerbation of IPF that removes the idiopathic requirement and focuses on the pathophysiological mechanism involved.

Entities:  

Keywords:  Acute exacerbation; Definition; Diagnosis; Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Management

Year:  2013        PMID: 24416637      PMCID: PMC3883625          DOI: 10.1007/s13665-013-0065-x

Source DB:  PubMed          Journal:  Curr Respir Care Rep        ISSN: 2161-332X


  51 in total

1.  Outcome of patients admitted to the intensive care unit for acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Fahad M Al-Hameed; Sat Sharma
Journal:  Can Respir J       Date:  2004-03       Impact factor: 2.409

2.  Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study.

Authors:  Marco Mura; Maria A Porretta; Elena Bargagli; Gianluigi Sergiacomi; Maurizio Zompatori; Nicola Sverzellati; Amedeo Taglieri; Fabrizio Mezzasalma; Paola Rottoli; Cesare Saltini; Paola Rogliani
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

3.  Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Keiji Oishi; Yuka Mimura-Kimura; Taku Miyasho; Keisuke Aoe; Yoshiko Ogata; Hideki Katayama; Yoriyuki Murata; Hiroshi Ueoka; Tsuneo Matsumoto; Yusuke Mimura
Journal:  Cytokine       Date:  2012-09-26       Impact factor: 3.861

4.  Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  J S Lee; J W Song; P J Wolters; B M Elicker; T E King; D S Kim; H R Collard
Journal:  Eur Respir J       Date:  2011-12-19       Impact factor: 16.671

5.  Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study.

Authors:  Susumu Sakamoto; Sakae Homma; Mingyon Mun; Takeshi Fujii; Atsuko Kurosaki; Kunihiko Yoshimura
Journal:  Intern Med       Date:  2011-01-15       Impact factor: 1.271

6.  Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Sharon Chao Wootton; Dong Soon Kim; Yasuhiro Kondoh; Eunice Chen; Joyce S Lee; Jin Woo Song; Jin Won Huh; Hiroyuki Taniguchi; Charles Chiu; Homer Boushey; Lisa H Lancaster; Paul J Wolters; Joseph DeRisi; Don Ganem; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2011-02-25       Impact factor: 21.405

7.  Two cases of acute exacerbation of interstitial pneumonia treated with polymyxin B-immobilized fiber column hemoperfusion treatment.

Authors:  Satoshi Noma; Wataru Matsuyama; Hideo Mitsuyama; Takayuki Suetsugu; Yoshimizu Koreeda; Keiko Mizuno; Ikkou Higashimoto; Yasuyuki Kakihana; Teruto Hashiguchi; Ikuro Maruyama; Mitsuhiro Osame; Kimiyoshi Arimura
Journal:  Intern Med       Date:  2007-09-03       Impact factor: 1.271

8.  Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Susumu Sakamoto; Sakae Homma; Atsushi Miyamoto; Atsuko Kurosaki; Takeshi Fujii; Kunihiko Yoshimura
Journal:  Intern Med       Date:  2010-01-15       Impact factor: 1.271

9.  Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.

Authors:  R W Tobin; C E Pope; C A Pellegrini; M J Emond; J Sillery; G Raghu
Journal:  Am J Respir Crit Care Med       Date:  1998-12       Impact factor: 21.405

10.  Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Authors:  Harold R Collard; Eric Yow; Luca Richeldi; Kevin J Anstrom; Craig Glazer
Journal:  Respir Res       Date:  2013-07-13
View more
  14 in total

1.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 2.  Management of interstitial lung disease associated with connective tissue disease.

Authors:  Stephen C Mathai; Sonye K Danoff
Journal:  BMJ       Date:  2016-02-24

3.  Staging and outcome in acute exacerbation of idiopathic pulmonary fibrosis: are all limits and determinants under control?

Authors:  Antonio M Esquinas; Alejandro Ubeda Iglesias; Angela Reina González
Journal:  Lung       Date:  2014-10-14       Impact factor: 2.584

4.  Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications.

Authors:  Loredana Raciti; Francesca Antonia Arcadi; Rocco Salvatore Calabrò
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

5.  Plasma Leptin Is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Authors:  Mengshu Cao; Jeffery J Swigris; Xin Wang; Min Cao; Yuying Qiu; Mei Huang; Yonglong Xiao; Hourong Cai
Journal:  Mediators Inflamm       Date:  2016-08-25       Impact factor: 4.711

6.  Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study.

Authors:  Frunze Petrosyan; Daniel A Culver; Anita J Reddy
Journal:  BMC Pulm Med       Date:  2015-07-10       Impact factor: 3.317

7.  Interstitial lung diseases in the hospitalized patient.

Authors:  Supparerk Disayabutr; Carolyn S Calfee; Harold R Collard; Paul J Wolters
Journal:  BMC Med       Date:  2015-09-25       Impact factor: 8.775

8.  Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach.

Authors:  Spyros A Papiris; Konstantinos Kagouridis; Likurgos Kolilekas; Andriana I Papaioannou; Aneza Roussou; Christina Triantafillidou; Katerina Baou; Katerina Malagari; Stylianos Argentos; Anastasia Kotanidou; Anna Karakatsani; Effrosyni D Manali
Journal:  BMC Pulm Med       Date:  2015-12-14       Impact factor: 3.317

9.  Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.

Authors:  Toby M Maher; Maria Molina-Molina; Anne-Marie Russell; Francesco Bonella; Stéphane Jouneau; Elena Ripamonti; Judit Axmann; Carlo Vancheri
Journal:  BMC Pulm Med       Date:  2017-09-15       Impact factor: 3.317

10.  IL-17A contributes to HSV1 infection-induced acute lung injury in a mouse model of pulmonary fibrosis.

Authors:  Tao Chen; Hui Qiu; Meng-Meng Zhao; Shan-Shan Chen; Qin Wu; Nian-Yu Zhou; Li-Qin Lu; Jia-Cui Song; Dan-Li Tang; Dong Weng; Hui-Ping Li
Journal:  J Cell Mol Med       Date:  2018-10-30       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.